Xenon-Induced Effects in Relieving Experimental Acute Respiratory Distress Syndrome.

Area of Science:

• Medical Research
• Pulmonology
• Anesthesiology

Background:

• Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition with high mortality.
• Current ARDS treatments are limited, necessitating novel therapeutic strategies.
• Inflammation and coagulation disorders are key pathological features of ARDS.

Purpose of the Study:

• To investigate the therapeutic effects of oxygen-xenon (70%/30%) mixture inhalations in ARDS models.
• To assess the impact of oxygen-xenon on lung inflammation and associated physiological parameters.
• To evaluate the influence of oxygen-xenon on thrombogenic stimuli and anticoagulant factors in ARDS.

Main Methods:

• Two models of acute respiratory distress syndrome were induced via intratracheal administration of lipopolysaccharide (LPS) or acidin-pepsin.
• Animals inhaled an oxygen-xenon (70%/30%) mixture.
• Lung weight, body weight, thrombogenic stimulus, and antithrombin III levels were measured.

Main Results:

• Oxygen-xenon inhalations significantly inhibited the development and reduced the intensity of lung inflammation.
• Therapeutic exposure to oxygen-xenon decreased both lung and body weight in the animal models.
• The thrombogenic stimulus, characteristic of ARDS, was reduced, while the natural anticoagulant antithrombin III level increased.

Conclusions:

• Oxygen-xenon (70%/30%) mixture inhalations demonstrate a protective and therapeutic effect against acute respiratory distress syndrome.
• This gas mixture mitigates lung inflammation and improves the coagulation balance in ARDS.
• Oxygen-xenon presents a promising novel therapeutic agent for managing acute respiratory distress syndrome.